BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the ...

The stock's recent trajectory tells a story of two very different forces. After hitting a 52-week low of €68.35 in March, the ...

Biotech stocks had already been gaining ground before this week’s news. In June, the iShares Nasdaq Biotechnology ETF (IBB) ...

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary ...

Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company.

BioNTech (BNTX) is back in focus after presenting new clinical data from its lung cancer program at the IASLC 2026 World ...

BioNTech (BNTX) stock rose after a Phase 3 trial win for an mRNA-based cancer shot from Moderna (MRNA) and Merck (MRK), a ...

The Department's proposal is not yet final. Children attending school must, for now, be vaccinated against the four diseases ...

Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.

A combination mRNA cancer vaccine from BioNTech and Regeneron may be one step closer to actualization based on initial Phase 2 results unveiled Tuesday. The mRNA-based vaccine, BNT111, in combination ...

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million. It ...

We investigated county-level variation in mRNA COVID-19 vaccine use among Medicare beneficiaries throughout the United States. There was greater use of Pfizer-BioNTech vaccines than Moderna vaccines ...